Literature DB >> 19170044

Lymph node assessment and lymphadenectomy in prostate cancer.

Michael Ordon1, Robert K Nam.   

Abstract

The role of lymph node assessment for patients with clinically localized prostate cancer has significantly evolved over the last 20 years. The status of pelvic lymph nodes primarily served as a prognostic marker for prostate cancer. Improved methods in assessing the risk for cancer progression and metastasis have enhanced our ability to identify patients who require pelvic lymphadenectomy during radical prostatectomy. The status of pelvic lymph nodes is also being used to guide further treatments after surgery. Also, recent data has shown possible therapeutic benefit of lymphadenectomy in improving cancer specific survival.

Entities:  

Mesh:

Year:  2009        PMID: 19170044     DOI: 10.1002/jso.21225

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

Review 1.  Biomarker research in prostate cancer--towards utility, not futility.

Authors:  Sheng Fei Oon; Stephen R Pennington; John M Fitzpatrick; R William G Watson
Journal:  Nat Rev Urol       Date:  2011-03       Impact factor: 14.432

2.  Is there a relationship between the number of lymph nodes and disease parameters in patients who underwent retropubic prostatectomy.

Authors:  Aslan Demir; Mert Ali Karadağ; Levent Türkeri
Journal:  Int Urol Nephrol       Date:  2014-03-25       Impact factor: 2.370

3.  Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.

Authors:  Ning Xu; Hui-Jun Chen; Shao-Hao Chen; Xue-Yi Xue; Hong Chen; Qing-Shui Zheng; Yong Wei; Xiao-Dong Li; Jin-Bei Huang; Hai Cai; Xiong-Lin Sun
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

4.  Increased Paxillin expression in prostate cancer is associated with advanced pathological features, lymph node metastases and biochemical recurrence.

Authors:  Qing-Shui Zheng; Shao-Hao Chen; Yu-Peng Wu; Hui-Jun Chen; Hong Chen; Yong Wei; Xiao-Dong Li; Jin-Bei Huang; Xue-Yi Xue; Ning Xu
Journal:  J Cancer       Date:  2018-02-28       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.